Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 22 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received marketing approval from COFEPRIS in Mexico for its Bevacizumab biosimilar, Bhava, to treat various cancers. The approval allows Zydus to market Bhava in different strengths for treating conditions such as metastatic colorectal cancer and non-small cell lung cancer. Dr. Sharvil Patel, Managing Director, emphasized the importance of this approval for improving access to affordable cancer therapies in Latin America. The press release highlights Zydus's commitment to developing biosimilars and addressing unmet healthcare needs in oncology.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 22, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Bhava (Bevacizumab biosimilar) to treat various cancers".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases